Abstract
Objectives. The objective of this study was to evaluate the potential use of Prostate Imaging – Reporting and Data System version 2 (PI-RADS) in combination with Glutathione S-transferase P1 (GST-P1) expression for an improved diagnosis of prostate cancer, in patients with inconclusive values of prostate-specific antigen (PSA). Materials and Methods. The study was conducted on 80 patients for whom PSA values were evaluated and were found to be inconclusive (4-10 ng/ml). These patients underwent imagistic evaluation (PI-RADS), followed by transurethral prostate biopsy, with the evaluation of GST-P1 expression and histopathological examination (for diagnosis confirmation). Results. By combining the results of PI-RADS and GST-P1 the capacity of the tests to correctly identify healthy subjects, with an area under curve of 0,832 (95% CI 0.732–0.907), with a sensitivity of 73,25% and a specificity of 77,78%. Conclusions. PI-RADS lesions and GST-P1 methylation testing when PSA levels are in a “grey zone”, provide a better specificity and sensitivity by comparison through single testing. Testing patients with inconclusive PSA levels allows for a more accurate diagnosis and less over-diagnosis by non-invasive procedures, such as repeated biopsies.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Recommended Citation
Stan, Marius; Botnarciuc, Vladimir; Suceveanu, Andra Iulia; Costea, Andreea Cristina; Suceveanu, Adrian Paul; Mazilu, Laura; Iorga, Ciprian; Hangan, Tony; Tudor, Corneliu; Epistatu, Dragos; Chirila, Sergiu; Gherghina, Viorel; and Voinea, Felix
(2022)
"Prostate Imaging Reporting and Data System score (PI-RADS) and Glutathione S-transferase P1 methylation status (GST-P1) in the diagnosis of prostate cancer patients with borderline PSA values,"
Journal of Mind and Medical Sciences: Vol. 9:
Iss.
2, Article 13.
DOI: https://doi.org/10.22543/2392-7674.1354
Available at:
https://scholar.valpo.edu/jmms/vol9/iss2/13
Included in
Medicinal and Pharmaceutical Chemistry Commons, Oncology Commons, Radiology Commons, Reproductive and Urinary Physiology Commons, Surgery Commons, Urology Commons